ReviewFrontiers in pharmacology2026
Chagas disease and amiodarone: a bibliometric and systematic review from cell to patient.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chagas disease (CD) is a neglected tropical illness caused by Methodology: This study combines bibliometric and systematic review approaches to explore the use of AMIO in the treatment of CD. The literature search was conducted in PubMed. Bibliometric analyses were performed using the Bibliometrix 2.2.1 package in R 3.6 (R Core Team, 2019). Relationship mapping was carried out using VOSviewer 1.6.16 (https://www.vosviewer.com/) to visualize bibliographic network structures. The systematic review component followed the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines. Principal Findings: A total of 52 original articles published in 35 journals were included, involving contributions from 269 authors, predominantly from Latin America. Brazil was the leading contributor, followed by Venezuela, the United States, Argentina, and Spain. The bibliometric analysis identified several emerging trends: (1) treatment outcomes such as mortality and hospitalization; (2) the antiarrhythmic effects of AMIO; (3) potential trypanocidal effects of AMIO; (4) the use of AMIO in combination with other drugs for etiological treatment; and (5) its possible anti-inflammatory effects. Conclusion: This review highlights a significant gap in literature, specifically the lack of rigorous clinical studies evaluating the impact of AMIO in patients with chronic Chagas cardiomyopathy (CCC). Additionally, we identify promising avenues for future research to better understand AMIO's therapeutic role in the management of CD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.